SCM
ACOR

Sigma Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Sigma Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,572
Closed -$6.22M – 374
2013
Q2 		$6.22M Buy
+1,572
New +$6.47M 0.29% 88

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sigma Capital Management's ACOR Position: Q3 2013 in Review

Sigma Capital Management sold out of Acorda Therapeutics (ACOR) in Q3 2013, closing a stake of 1,572 shares — an estimated $6.22M sold.

Sigma Capital Management first reported a position in ACOR in Q2 2013 and held it in 1 quarter. The position peaked at $6.22M in Q2 2013. 153 funds tracked by Wall St. Rank hold ACOR as of Q3 2013.

  • Sigma Capital Management reported no remaining Acorda Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Sigma Capital Management sold 1,572 Acorda Therapeutics shares in Q3 2013, an estimated $6.22M.
  • Sigma Capital Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 1 quarter.
  • Sigma Capital Management's Acorda Therapeutics position peaked at $6.22M in Q2 2013.
  • 153 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2013.

Based on Sigma Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.